Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
P/B ratio for Chugai Pharmaceutical Co., Ltd. (4519.T)
P/B ratio as of 2023: 5.41
According to Chugai Pharmaceutical Co., Ltd.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.41. At the end of 2022 the company had a P/B ratio of 3.89.
P/B ratio history for Chugai Pharmaceutical Co., Ltd. from 2003 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 5.41 |
| 2022 | 3.89 |
| 2021 | 5.17 |
| 2020 | 9.23 |
| 2019 | 6.46 |
| 2018 | 4.62 |
| 2017 | 4.56 |
| 2016 | 2.84 |
| 2015 | 3.70 |
| 2014 | 2.71 |
| 2013 | 2.21 |
| 2012 | 1.84 |
| 2011 | 1.51 |
| 2010 | 1.81 |
| 2009 | 2.19 |
| 2008 | 2.37 |
| 2007 | 2.28 |
| 2006 | 3.52 |
| 2005 | 3.84 |
| 2004 | 2.93 |
| 2003 | 2.86 |